Skip to search formSkip to main contentSkip to account menu

NPI 2358

Known as: (3Z,6Z)-6-benzylidene-3-{[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylidene}piperazine-2,5-dione, NPI-2358, NPI2358 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Diketopiperazines

Narrower (1)

plinabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
8054 Background: Plinabulin (N) inhibits tumor growth by targeting both angiogenesis and tumor vasculature as well as directly by… 
Highly Cited
2012
Highly Cited
2012
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
SummaryBackground Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) that destabilizes tumor vascular endothelial cell… 
Highly Cited
2012
Highly Cited
2012
Synthesis and Structure−Activity Relationship Study of Antimicrotubule Agents Phenylahistin Derivatives with a Didehydropiperazine-2,5-dione Structure
Plinabulin (11, NPI-2358) is a potent microtubule-targeting agent derived from the natural diketopiperazine “phenylahistin” (1… 
2012
2012
Unusual expression of red fluorescence at M phase induced by anti-microtubule agents in HeLa cells expressing the fluorescent ubiquitination-based cell cycle indicator (Fucci).
2011
2011
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation
Abstract Purpose: This study investigated the anti-tumour effects of the novel vascular disrupting agent plinabulin (NPI-2358… 
Highly Cited
2010
Highly Cited
2010
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Purpose: Plinabulin (NPI-2358) is a vascular disrupting agent that elicits tumor vascular endothelial architectural… 
2010
2010
Anti-microtubule 'plinabulin' chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin.
Review
2009
Review
2009
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Targeting vasculature, essential in oxygen and nutrient supply, represents a new frontier in the treatment of cancer. Apart from… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
Highly Cited
2006
Highly Cited
2006
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent
The diketopiperazine NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)